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Article
Modifying three-dimensional scaffolds
from novel nanocomposite materials
using dissolvable porogen particles for
use in liver tissue engineering
Hussamuddin Adwan1, Barry Fuller1, Clare Seldon2,
Brian Davidson1 and Alexander Seifalian1
Abstract
Background: Although hepatocytes have a remarkable regenerative power, the rapidity of acute liver failure makes liver
transplantation the only definitive treatment. Attempts to incorporate engineered three-dimensional liver tissue in
bioartificial liver devices or in implantable tissue constructs, to treat or bridge patients to self-recovery, were met
with many challenges, amongst which is to find suitable polymeric matrices. We studied the feasibility of utilising
nanocomposite polymers in three-dimensional scaffolds for hepatocytes.
Materials and methods: Hepatocytes (HepG2) were seeded on a flat sheet and in three-dimensional scaffolds made of
a nanocomposite polymer (Polyhedral Oligomeric Silsesquioxane [POSS]-modified polycaprolactone urea urethane)
alone as well as with porogen particles, i.e. glucose, sodium bicarbonate and sodium chloride. The scaffold architecture,
cell attachment and morphology were studied with scanning electron microscopy, and we assessed cell viability and
functionality.
Results: Cell attachment to the scaffolds was demonstrated. The scaffold made with glucose particles as porogen
showed a narrower range of pore size with higher porosity and better inter-pore communications and seemed to
encourage near normal cell morphology. There was a steady increase of albumin secretion throughout the experiment
while the control (monolayer cell culture) showed a steep decrease after day 7. At the end of the experiment, there was
no significant difference in viability and functionality between the scaffolds and the control.
Conclusion: In this initial study, porogen particles were used to modify the scaffolds produced from the novel polymer.
Although there was no significance against the control in functionality and viability, the demonstrable attachment on
scanning electron microscopy suggest potential roles for this polymer and in particular for scaffolds made with glucose
particles in liver tissue engineering.
Keywords
POSS-modified polycaprolactone urea urethane, nanocomposite polymers, hepatocytes, tissue engineering, scaffolds,
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Introduction
Deaths from chronic liver disease (CLD) have increased
by eight times in men and seven times in women over
the past three decades, while the immediate mortality of
acute liver disease (ALD) is in the range of 25–50%,
patients with fulminant hepatic failure usually die with-
out transplantation.1,2 Liver transplantation remains
the only eﬀective treatment for ALD and CLD, but
many patients on the liver transplant list die whilst
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waiting for a graft. In the UK alone, between 1 April
2006 and 31 March 2007, there was a total of 1199
patients awaiting transplantation, of which only 649
patients (54%) received transplantation while 99
patients died (8%).3 Thus, bioartiﬁcial liver (BAL)
tissue-engineered replacements could have a huge
impact on the outcome of liver failure. Despite many
on-going clinical trials into a number of BAL devices,
none of them has been approved for clinical practice.4–13
The importance of polymeric matrices in the process
of developing three-dimensional (3D) scaﬀolds is fur-
ther highlighted by the fact that hepatocytes are attach-
ment-dependent and lose their liver-speciﬁc function
without optimal media and extracellular matrix
(ECM) composition and cell-cell contacts.14–21 It was
observed that the 3D matrix architecture inﬂuences the
function and diﬀerentiation of liver cells in vitro.
Hence, combining cell transplantation with 3D, highly
porous polymeric matrices became an appealing con-
cept.20,22–24 Therefore, the search continues to ﬁnd the
ideal polymer that would allow a high density of hep-
atocytes to maintain their viability and function and
encourage neo-tissue formation. It has been agreed
that the ideal scaﬀold should be biocompatible and
highly porous with more controllable pore size ranging
from 200 to 400 mm.7,9–13,21,25–41
Our laboratory has developed a novel nanocompo-
site biodegradable scaﬀold namely POSS-modiﬁed
polycaprolactone urea urethane (PU) made by integrat-
ing Polyhedral Oligomeric Silsesquioxane (POSS)
[a trademark of Hybrid Plastics (www.hybridplastics.
com)], a cytocompatible polymer nanoﬁller with poly-
"-caprolactone (PCL), a biodegradable and nontoxic
aliphatic polyester, that can produce highly porous
scaﬀolds.42–49
This study examined the suitability of this novel
polymer and its porogen modiﬁcations as potential
scaﬀolds for bioengineered liver. The architecture and
porosity of the new scaﬀolds were examined under
scanning electron microscopy (SEM) and the anchor-
age, viability and functionality of seeded hepatocytes
were studied on these novel scaﬀolds in a static culture
using SEM and a number of viability and functionality
assays.
Methods
Polymer preparation, coagulation and construction
Making 2D discs. Discs of polymer were formed by
spreading the polymer at 15% concentration in solvent
over Melinex sheets supported by stainless steel plates,
coagulated by slow immersion in distilled water at
room temperature and cut (the polymer attached to
the Melinex sheet as PMS) at 15-mm diameter for use
into 24-well tissue culture plates (TCPs). Shaped PMS
pieces were kept moist and placed in covered glass Petri
dishes, autoclaved and kept sterile until needed; 15mm
discs from Melinex sheets alone (Melinex) and normal
TCPs were used as control.
Making 3D scaffolds. The polymer (PU) at 10% concen-
tration in solvent and three diﬀerent modiﬁcations were
made by adding porogens to PU at 1:1 weight ratio to
produce four diﬀerent scaﬀolds. The combined polymer
and porogens were mixed manually then on a horizon-
tal rotator for 1–2 h to produce a polymer with glucose
(PG), sodium bicarbonate (PB) and with sodium chlor-
ide (PN); 15-mm discs were made by coagulating a
4.5–5 g spread of the mixtures into 5.5 cm diameter
glass Petri dishes in distilled water overnight. Each of
the four mixtures was coagulated in a dedicated water
bath that was changed prior to cutting to shape four
times lasting 30min each time. The discs were then
shaved oﬀ from two opposite sides to allow more con-
tact with culture media. Scaﬀolds were kept moist,
sealed in glass Petri dishes, and autoclaved.
Cell culturing conditions and cell seeding
Cell culturing, passaging and maintenance. HepG2
cells were cultured in growth medium (GM)
made of DMEMþGlutaMAXTM Media (GIBCO,
InvitrogenTM) with 10% foetal bovine serum
(GIBCO, InvitrogenTM) and PenStrep at concentra-
tion of 100 Unit þ 100 mg/ml of penicillin and strepto-
mycine, respectively (10,000 Unit/ml penicillin and
10,000 mg/ml streptomycin, GIBCO, InvitrogenTM).50
GM was changed over the culture every 3–4 days and
the cells were passaged at 60–80% conﬂuence.
HepG2 cell seeding. The scaﬀolds were covered with GM
in 24-well TCPs (Costar, Corning Inc.) and incubated
at 37C and 5% CO2 overnight prior to moving them to
a fresh 24-well plates for cell seeding. A 0.1ml of homo-
genized HepG2 cells in GM at 10 104 cells/100 ml cal-
culated using a haemocytometer were injected into each
of the scaﬀolds and left to settle for 15–30min, then
topped up with 0.9ml GM and incubated for 24 h.
They were then carefully transferred into a pre-pre-
pared 24-well plates with four wells already seeded
with 10 104 cells/ml of GM and kept in similar con-
ditions to the seeded scaﬀolds as control in TCPs. All
wells were topped up to 2ml of GM and incubated at
37C and 5% CO2. The day when the seeded 3D scaf-
folds were transferred into the pre-prepared wells was
counted as day zero. Initial naked eye observation
was used to assess the adequacy of the seeding process
and further conﬁrmation was made by comparing
ﬂuorescence intensity (FI) percentage diﬀerence on
Adwan et al. 251
 at University College London on August 4, 2014jba.sagepub.comDownloaded from 
alamarBlue assay from randomly selected seeded scaf-
folds and from control in TCP on day 1.
Characterisation of the scaffolds and the seeded
hepatocytes
Porosity calculation. An estimate of porosity was calcu-
lated by the formula:
Percentage Porosity
¼ ðVol:Solventþ Vol:PorogenÞ  100
T:Vol:Polymer
Scanning electron microscopy. Pore sizes, pore wall thick-
ness, inter-pore communications and hepatocytes
anchorage, proliferation and cell-cell attachments
were evaluated and described using SEM digital pho-
tography at 40, 320, 640 and 1250 times magniﬁcations.
Samples were ﬁxed in 1.5% glutaraldehyde for a min-
imum of 2 h, washed with several changes of phos-
phate-buﬀered saline and postﬁxed using 1% osmium
tetroxide/1.5% potassium ferricyanide for 12 h.
Samples were then washed with distilled water and
dehydrated through graded alcohols. Control samples
were ﬁxed using graded alcohol dehydration starting at
70%. All samples were then attached to aluminium
stubs with double-sided sticky tabs (TAAB) and then
coated with gold using an SC500 (EMScope) sputter
coater before being examined and photographed using
a Philips 501 scanning electron microscope.
Assessment of hepatocytes viability, proliferation
and functionality
AlamarBlue and PicoGreen assays. HepG2 metabolic
activities, proliferation and growth and scaﬀold cyto-
toxicity were assessed using alamarBlue assay
(Molecular Probes, Invitrogen) on days 1, 3, 7 and
14. A standard curve was worked out experimentally
which suggested 4 h incubation period for the HepG2
cell line to be the optimum timing to measure the FI
for alamarBlue. Further quantiﬁcation of the cell-
line proliferation was made by quantitating double-
stranded DNA (dsDNA) using PicoGreen assay
(Quant-iTTM PicoGreen dsDNA Assay Kit,
Molecular Probes, Invitrogen) on culture D10 of
experiments on PMS and on culture D7 and D14 of
experiments on the 3D scaﬀolds.
FI was measured using a ﬂuorescence plate reader
(Fluoroskan Ascent FL, and Ascent Software,
Thermo Labsystems, Helsinki, Finland) at 530 nm exci-
tation wavelength and 620 nm emission wavelength for
alamarBlue and at 485 nm excitation and 538 nm
emission for PicoGreen. We used the means of the
actual FI measurements in plotting for the graphs
and charts and the percentage diﬀerence was calculated
from the following equation:
Percentage Difference ¼ FI of the tested sample 100
FI of the control sample
Measurement of aspartate transferase, albumin and
urea in supernatant medium
Human albumin ELISA assay. Albumin secretion from 3D
scaﬀolds and their control in TCP were measured using
Human Albumin ELISA Quantiﬁcation Kit (Bethyl
Laboratories, Inc., Montgomery, USA) using manufac-
turer’s protocol.
Urea synthesis and aspartate transferase. Modular ana-
lytics clinical chemistry system (Roche Diagnostics,
Basel, Switzerland) was used to measure urea and
aspartate transferase (AST) levels in the GM super-
natant from 3D scaﬀolds and their control in TCP.
Statistical analysis and software
GraphPad PRISM Version 5.0 (GraphPad Software,
Inc., San Diego, USA) was used for statistical analysis
and graph illustration. Unless stated otherwise, samples
were made in quadruplets (n4) and statistical analysis
was performed at 95% CI. Data was initially analysed
using Kruskal-Wallis test and further speciﬁc pairwise
post-hoc comparisons were carried out as needed using
Dunn’s Multiple Comparison test or Mann Whitney U
test.51
Results
Scaffolds characterisation
Using the percentage porosity equation, we estimated
the porosity of PG, PB and PN to be around 95% while
that of the PU to be around 90%. The scaﬀold made by
using glucose as porogen (PG) demonstrated a better
architecture than the other scaﬀolds by means of better
porosity with most of pore sizes above 200 mm (ranging
from 100–350mm), highly communicative porous struc-
ture and pore walls as thin as 1.2–12 mm. The other
scaﬀolds were relatively far oﬀ the ideal scaﬀold archi-
tecturally. PU scaﬀolds had a large pore size ranging
from 500 mm–2mm, distinctly thick pore walls towards
the surface of the polymer (170–650 mm) but thinner
towards the lower half of the polymer (10–100 mm),
with limited inter-pore communications, and pores
were lined with clusters of spherical bodies ranging in
size from 2 to 5 mm. PB and PN scaﬀolds had extremely
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Figure 1. Scanning electron microscopy (SEM) at (1) 40 and (2) 320 times magnifications of transverse sections of the 3D scaffolds:
(a) polycaprolactone urea urethane (PU), (b) polymer with glucose (PG), (c) sodium bicarbonate (PB) and (d) sodium chloride (PN).
The pores and the wall thickness are largest in PU and finest in PB while PN shows a distinct layer of fine pores on top of a layer of
much larger pore sizes. Only PG demonstrated a nearly uniformal mixture of pore sizes which is neither very large nor very small,
along with a narrower range of wall thickness and more interpore communications. Although PB at higher magnification demonstrated
higher interpore communications, the overall pore sizes were either too small or too large, rendering their support to cells and their
influence on hepatocytes’ proliferation less uniformal and hence less predictable.
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variable pore sizes (20–750 mm and 150 mm–1.5mm,
respectively; Figure 1).
Cell seeding and cell characterisation
Complete seeding in TCP and on 2D scaﬀolds was
observed, but a small fraction of the homogenised solu-
tion leaked from the shaved sides of the 3D scaﬀolds.
A general estimate of this leak was extrapolated by
comparing FI percentage diﬀerence on alamarBlue
assay on day 1.
On culture D8, near-complete hepatocyte conﬂuence
was demonstrated on 2D (monolayer) culture on PMS
comparable to control on Melinex (Figure 2).
Hepatocytes morphology, polyhedral characterisation,
cell-cell and cell-matrix attachment were observed on
higher SEM magniﬁcation on 2D PMS and in 3D scaf-
folds with numerous cells attached to the scaﬀolds’
porous structures (Figure 3 and 4). Cells were observed
to form healthier colonies with smoother surfaces and
higher incidence of cell aggregates on PG scaﬀolds
when compared with other scaﬀolds (Figure 4).
Cell viability, proliferation and functionality
assessments
AlamarBlue and PicoGreen assays. The mean FI emis-
sion from control in TCP was higher than from control
in Melinex throughout on alamarBlue assay and on
culture D10 on PicoGreen assay, but the diﬀerences
Figure 2. Scanning electron microscopy (SEM) at 80 times magnification on Day 5, 8 and 10 (1, 2 and 3, respectively) comparing
hepatocytes’ confluence and proliferation on (a) PMS and (b) Melinex. The rate of proliferation of hepatocytes on PMS seems similar if
not higher than on Melinex as indicated by the near complete cell confluence on Day 8 on PMS. The cracks noted between cell
aggregates on PMS on Day 8 and 10 could be a combination of the alcohol dehydration process used to prepare the slides for SEM and
an overlap of cell growth.
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Figure 4. Scanning electron microscopy (SEM) at 2500 magnification demonstrating cell-cell and cell-matrix attachment on culture
Day 7 of HepG2 in the three-dimensional (3D) nanocomposite scaffolds: POSS-modified polycaprolactone urea urethane (PU) (a) and
its porogen modifications, i.e. with glucose particles (PG) (b), with sodium bicarbonate particles (PB) (c) and with sodium chloride
particles (PN) (d). The cell surface looks smoother and has less granulation in PU and in PG. The cracks within HepG2 sheets could
have been from the alcohol dehydration process during sample preparation for SEM.
Figure 3. Scanning electron microscopy (SEM) at 640 (a) and (b) and at 2500 magnifications (c) and (d) on culture Day 3 on PMS.
HepG2 hepatocytes seem to retain their phenotypical hexagonal appearance. Cell-cell and cell-matrix attachments on PMS can also be
observed especially around the peripheries of cell clusters and with more clarity in (d).
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were not signiﬁcant and both control produced com-
parable graphs with matching trends on alamarBlue
suggesting that Melinex is a suitable alternative to com-
pare with PMS in SEM evaluation. Culture on PMS
demonstrated progressive FI emission in alamarBlue
assay and on culture D8 mean FI measured was signiﬁ-
cantly higher than on D2 (88.33 vs. 52.65 U/L, respect-
ively, Mann-Whitney p¼ 0.0286). Although the mean
FI measured from Melinex was signiﬁcantly higher
than from PMS on two occasions, culture D3 and D8
(Kruskal-Wallis p¼ 0.0207 and 0.0218, respectively;
Dunn’s multiple comparison test p< 0.05 for
each), they produced graphs with similar trends
(Graph 1(a)). On culture D10 there was little diﬀerence
in mean FI emission between PMS and Melinex on
PicoGreen assay (46.74 vs. 50.65 U/L, respectively,
FI percentage diﬀerence 92.28, Mann-Whitney
p¼ 0.3429), which was not in line with the much
higher diﬀerence found on alamarBlue assay (50.94
vs. 98.40 U/L, respectively, FI percentage diﬀerence
51.77; Graphs 1(a) and 2(a).
All 3D scaﬀolds cultures demonstrated progressive
FI emission on alamarBlue assay up to the end of the
experiment on culture D14 and the higher mean FI
emission from control in TCP losses its signiﬁcance
when compared to most of the scaﬀolds on culture
D14 (Graph 1(b)). There was a signiﬁcantly higher
mean FI emission from control in TCP than from
most of the scaﬀolds on culture D7, but the higher
mean FI emission from control in TCP on
PicoGreen assay showed a narrower non-signiﬁcant
diﬀerence (i.e. higher FI percentage diﬀerence) than
on alamarBlue on culture D7 (Graph 2). There was
a clear increase in FI emission on PicoGreen from
all the scaﬀolds on culture D14 as compared to D7
(Graph 2(b)).
AST secretion. Mean AST production was notably low
across the board on culture D1, D3 and D14, with a
transient relative increase from control in TCP and
from PG scaﬀold on D7 when compared to other scaf-
folds (Graph 3(a)).
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Graph 1. Summary graphs representing the results of alamarBlue assay: (a) Examining PMS in 2D cultures against two different
controls, in Meliniex and in tissue culture plates (TCPs). Although fluorescence intensity (FI) emissions were higher from control in
Melinex and in TCP than from PMS, there was little, if any, difference between the two controls and both controls exhibit a similar
graph trend, rendering control in Melinx as a suitable alternative for control in TCP, especially for scanning electron microscope (SEM)
examination. FI emission from PMS was significantly higher on culture D5 and D8 when compared to D1, suggesting PMS capacity to
maintain hepatocytes for that period. Although FI emissions from control in TCP were significantly higher (*) than from PMS on
culture D2, D5 and D10 (mean FI percentage difference was 45.22, 57.79 and 48.54, respectively), and FI emissions from control in
Melinex were significantly higher (**) than from PMS on culture D3 and D8 (mean FI percentage difference was 55.89 and 58.89,
respectively), the graph trend of FI emissions exhibited from PMS is similar to that demonstrated by control in TCP and in Melinex.
(b) Examining the three-dimensional (3D) scaffolds and their control in TCP, FI emissions from control in TCP were significantly higher
than emissions from the scaffolds throughout the experiment, which could be explained by the leak of the homogenised cell solution at
the beginning of the experiment (FI percentage difference of the means on culture D1 between TCP and polymer with glucose (PG),
sodium bicarbonate (PB), sodium chloride (PN) and polycaprolactone urea urethane (PU) was 35.12, 19.31, 42.48 and 21.95,
respectively). However, all 3D scaffolds continue to demonstrate FI emission on alamarBlue up to culture D14, suggesting their
capacity to maintain hepatocytes for the length of the experiment. This is further supported by the reduction in the difference of FI
emission (i.e. larger FI percentage difference) between most of the scaffolds and control in TCP (FI percentage difference of the means
on culture D14 between TCP and PG, PB, PN and PU was 44.78, 54.33, 36.66 and 47.74, respectively).
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Albumin ELISA secretion. There was a signiﬁcant increase
in albumin production from all 3D scaﬀolds and their
control in TCP on culture D7 and D14 as compared to
D1 (Kruskal-Wallis p¼ 0.0030; Dunn’s multiple com-
parison test p< 0.05), suggesting the progressive prolif-
eration of viable hepatocytes in all the scaﬀolds.
Albumin production peaked on culture D7 across all
samples but declined across the board at the end of the
experiment on D14. The decline was much greater from
control in TCP than from the scaﬀolds of which PG
showed the smallest decline (Graph 3(b)).
Urea synthesis. A signiﬁcant increase of urea synthesis
on culture D7 and D14 from all scaﬀolds and the con-
trol in TCP was observed in comparison to urea syn-
thesis on D1 (Kruskal-Wallis p¼ 0.0006; Dunn’s
multiple comparison test p< 0.05; Graph 3(c)).
Pairwise post-hoc comparison suggested a signiﬁcantly
higher urea synthesis on culture D14 from control in
TCP in comparison to urea synthesis from PG, PB and
PU scaﬀolds (Mann Whitney Test p¼ 0.0408, 0.0294
and 0.0294 for each, respectively).
Discussion
This is the ﬁrst study to demonstrate the maintenance
of viable and functional hepatocytes on a novel
nanocomposite polymer i.e. POSS-modiﬁed polycapro-
lactone urea urethane. We opted to use human HepG2
cell line for their similar morphology to adult primary
hepatocytes, their tendency to attach and their albu-
min-synthesizing capacity, although their ammonia
detoxiﬁcation and mixed function oxidase activities
were very poor.52 These cells also undergo cell division
(which is not the case for primary hepatocytes) and
therefore allowed us to assess the potential scaﬀolds
for their ability to support increasing cell numbers.
This has relevance to the future hope of being able to
use stem cells or partially committed progenitor cells at
scale-up to provide liver support systems. On examin-
ing polymer-coated Melinex disks (PMS) and control
on Melinex disks and in TCP, there was a statistically
signiﬁcant higher FI emission from control in TCP and
to some extent from control on Melinex than from
PMS on both alamarBlue and PicoGreen; however,
they all exhibited a similar trend with a matching
trend on alamarBlue. This would suggest that the poly-
mer might have a dampening eﬀect on the ﬂuorescence
signal. In line with this possibility is the observation
that the percentage diﬀerence between PMS and TCP
on day 10 on PicoGreen assay was 81.17%, nearly
double that of alamarBlue, which was 48.54%, for
the same day and samples. Additionally, the SEM
demonstrated near-complete conﬂuence of hepatocytes
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Graph 2. A bar chart and a graph representing PicoGreen assay reflecting the relative quantity of HepG2 cells in cultures as indicated
by quantifying FI emissions of released cellular DNA’s following induced cell destruction. (a) Comparison between fluorescence
intensity (FI) emission from PMS and control in tissue culture plates (TCP) and in Melinex on culture D10 (at the end of the initial
experiment). Although, mean FI emission from PMS was lower than from control in Melinex and significantly lower than from control
in TCP (46.74, 50.65 and 57.59 U/L respectively; Kruskal-Wallis p¼ 0.0183; Dunn’s multiple comparison test p< 0.05 for PMS vs.
TCP), the difference between the three cultures on PicoGreen was much less than the difference found on alamarBlue (i.e. higher FI
percentage difference: 92.28 for PMS vs. Melinex and 81.16 for PMS vs. TCP). (b) A graph comparing FI emissions from each of the 3D
scaffolds with each other and with control in TCP on culture D7 and D14. Factoring in the initial low count of HepG2 cells at the
beginning of the experiment (due to the small unquantifiable leak of the homogenised solution at the time of seeding), a higher but
non-significant FI emission from control in TCP than from the scaffolds was anticipated. However, FI emissions were higher on culture
D14 than on D7 across all the 3D scaffolds suggesting progressive increase in HepG2 cell count and the maintenance of viable cell
culture for the duration of the experiment.
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by culture D8 and it showed clear cell-cell and cell-
matrix attachment on PMS. The fact that hepatocytes
retained their polyhedral shape and have less overriding
cells when compared with Melinex further suggests that
FI emission on alamarBlue assay may not have
reﬂected the actual cellular viability and as such may
not have been the most appropriate assay for this poly-
mer. These observations were taken into account when
planning for and analysing further experiments on 3D
scaﬀolds.
The novel use of porogens in the making of these 3D
scaﬀolds depends on the choice of non-toxic particles
that would dissolve in water during the polymer coagu-
lation process leaving behind a porous structure with
more controlled range of pore sizes. Of all the three
particles chosen, glucose is the one that would be the
most inert for hepatocytes if it did not dissolve com-
pletely. Although all 3D scaﬀolds exhibit striking archi-
tectural diﬀerences, PG scaﬀolds showed more
favouring architecture for the narrower range of their
pore sizes, numerous interpore communications and
their relatively thin interpore walls. While SEM exam-
ination demonstrated cell attachment on all scaﬀolds,
hepatocytes seeded on PG scaﬀolds tend to have a
smoother outline.
In all the experiments carried out to evaluate the
viability and the functionality of the seeded hepato-
cytes, control in TCP had a higher rate of FI emissions
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Graph 3. Summary graphs representing aspartate transferase (AST), albumin and urea synthesis (a, b and c, respectively) from
seeded 3D scaffolds on culture Day 1, 3, 7 and 14. AST is not commonly used to study static tissue culture. Unlike albumin and urea
synthesis where a high level reflects progressive proliferation of functioning hepatocytes, a high AST level should indicate an increased
number of damaged hepatocytes. Hence by simple deduction, continuous synthesis of AST requires progressive hepatocyte prolif-
eration. This could explain the rapid decline following the initial steady rise. The coincidental rapid decline of albumin secretion from
control in TCP detected on culture D14 after its initial increase on culture D7 would support this analogy (3.0, 14.125 and 8.0 U/L
mean AST release vs. 680.81, 15,259 and 9467.95 ng/ml mean albumin secretion from control in TCP on culture D1, 7 and 14,
respectively). The AST (a) and similarly albumin synthesis (b) exhibited plateau from 3D scaffolds after culture D7 would indirectly
suggest progressive proliferation of functioning hepatocytes. This is further supported by the gradual increase in urea synthesis across
all scaffolds (c). In all these experiments, AST, albumin secretion and urea synthesis were all higher from PG scaffolds when compared
to other scaffolds (highest on culture D7). The higher levels detected from control in TCP possibly reflects the initial small
unquantifiable loss of homogenised cell solution at the time of cell seeding into 3D scaffolds.
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in comparison to emissions from the scaﬀolds.
However, lack of signiﬁcance in the diﬀerence between
control in TCP and scaﬀolds in the presence of demon-
strable progressive increase in albumin, urea and AST
production across all the scaﬀolds suggest that hepato-
cytes maintained viability and functionality within
these scaﬀolds. A number of observations in this
study suggest continuing and progressive proliferation,
viability and functionality of hepatocytes when seeded
onto these scaﬀolds, especially onto PG scaﬀolds.
These observations include the progressive increase in
cell population as evidenced by a higher FI emission on
culture D14 than on D7 on PicoGreen; the clear dis-
crepancy between FI emissions and FI percentage dif-
ference on PicoGreen when compared to that from
alamarBlue; the potential dumping eﬀect of the new
polymer on FI emissions for alamarBlue assay sug-
gested by experiments on PMS and the clear SEM dem-
onstration of cell attachments to the porous structures
of the scaﬀolds.
A clearer demonstration was noted with albumin
secretion when the signiﬁcant increase in its production
on culture D7 from control in TCP was followed by a
steep decline a week later, which was not matched by an
equivalent reduction from the scaﬀolds. The scaﬀolds,
on the other hand, continued to demonstrate progres-
sive production of albumin throughout the experiment.
Although HepG2 cells are not known for their urea
synthesis ability, there was a progressive secretion at a
relatively similar rate from all the scaﬀolds throughout
the experiment. As the native polymer is based on a
urea compound, its exact inﬂuence on urea level is dif-
ﬁcult to predict and remains to be further investigated.
The use of AST in evaluating in vitro hepatocyte cul-
ture albeit novel is not without diﬃculty in interpreting
its signiﬁcance. When we decided to use it we antici-
pated a high level to be predictive of a higher rate of
hepatocyte damage. The production of AST, however,
gave a similar graph shape to that of albumin secretion.
On one hand it was anticipated that AST would be
higher from control in TCP as cell proliferation in 2D
culture is more likely to reach conﬂuence sooner than
on 3D scaﬀolds. On the other hand, albumin secretion
peaked as AST secretion reached its highest level from
control in TCP. Perhaps the sharp decline in both AST
and albumin secretion from control in TCP indicated
that cells in TCP had reached their maximum potential,
while the steady progressive production of albumin and
AST from the scaﬀolds was suggestive of the scaﬀolds’
potential to support hepatocytes’ functionality and via-
bility in culture for a longer period and this needs fur-
ther evaluation. It was notable that scaﬀolds made with
glucose (PG) had a relatively higher rate of albumin
and AST production when compared to the other
scaﬀolds.
Conclusion
We found that the use of dissolvable porogen particles
in developing 3D scaﬀolds from POSS-modiﬁed poly-
caprolactone urea urethane polymer modiﬁes the scaf-
folds’ properties and allows liver cell attachment and
functionality in particular when combined with glucose
as a porogen. However, this is a new polymer and more
work is needed to establish the best method for leaching
and coagulation and the most eﬃcient way to assess cell
count and viability within the scaﬀold structure. We
think that this polymer when combined with glucose
has the potential to be used in liver tissue engineering.
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